---
title: Pathophysiology and Risk of Atrial Fibrillation Detected After Ischemic Stroke
nct_id: NCT03275155
overall_status: ACTIVE_NOT_RECRUITING
sponsor: "London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's"
study_type: OBSERVATIONAL
primary_condition: Stroke, Ischemic
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03275155.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03275155"
ct_last_update_post_date: 2025-04-01
last_seen_at: "2026-05-12T06:45:13.613Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Pathophysiology and Risk of Atrial Fibrillation Detected After Ischemic Stroke

**Official Title:** The PAthophysiology and Risk of Atrial Fibrillation Detected After Ischemic StrokE (PARADISE): Prospective Non-interventional Cohort Study

**NCT ID:** [NCT03275155](https://clinicaltrials.gov/study/NCT03275155)

## Key Facts

- **Status:** ACTIVE_NOT_RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Collaborators:** Western University, Canada, London Health Sciences Centre, Parkwood Hospital, London, Ontario, El Instituto de Neurociencia Cognitiva y Traslacional (INCYT), Instituto de Neurologia Cognitiva (INECO)
- **Conditions:** Stroke, Ischemic, Transient Ischemic Attack, Atrial Fibrillation
- **Start Date:** 2017-04-18
- **Completion Date:** 2026-05-07
- **CT.gov Last Update:** 2025-04-01

## Brief Summary

This prospective non-interventional cohort study investigates the pathophysiology of Atrial Fibrillation Detected After Stroke or transient ischemic attack (AFDAS) by comparing the autonomic function and inflammation between patients with AFDAS, patients with atrial fibrillation (AF) diagnosed before the ischemic event or known AF (KAF), and patients with normal sinus rhythm (NSR) after 14 day of cardiac monitoring following the event onset.

## Detailed Description

This study enrolls patients with acute ischemic stroke at the London Health Sciences Center in London, Ontario, Canada. The heart rhythm of the patients is monitored with a CardioSTAT® Holter device (Icentia) for 14 days after the ischemic event onset. Based on this cardiac monitoring and previous medical history, patients are stratified into three groups: (a) atrial fibrillation detected after stroke or transient ischemic attack (AFDAS), (b) atrial fibrillation diagnosed before the ischemic event or known AF (KAF), and (c) normal sinus rhythm (NSR).

Autonomic function is assessed by the levels of plasma catecholamines, a battery of validated autonomic tests \[autonomic reflex screening (ARS)\], heart rate variability (HRV) through data obtained by Holter monitoring by standard quantitative analysis methods according to the guidelines of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology and by the analysis of diurnal variation of heart rate. Blood samples are collected for the analysis of inflammatory markers (e.g. CRP, TNF-α, IL-1β, and IL-6), and potential AFDAS predictors such as brain natriuretic peptide (BNP- AFDAS biomarker), endothelin-1 (endothelial dysfunction marker), Lipoprotein(a) \[Lp(a)\] and thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels, TAFI activity, TAFI single nucleotide polymorphisms (SNPs), apo(a) isoform size and plasma catecholamines levels. Furthermore, specific neuroimaging findings (e.g., specific regions of the insula or its connections) and clinical features (e.g., impaired interoceptive processing, cognitive impairment, etc) are also analyzed. Interoception is assessed using a heartbeat detection task without feedback condition and gait, balance, frailty, and cognitive status in patients are evaluated by the administration of a battery of tests. Stroke recurrence will be assessed by a structured phone interview at 6 and 12 months after the initial stroke.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. MCA territory-transient ischemic attack or -acute ischemic stroke patients seen in the Emergency Department or admitted to University Hospital, London, Ontario, Canada
2. Age ≥ 18 years old
3. Patient or Substitute Decision Maker must give written informed consent

Exclusion Criteria:

1. Patients with autonomic dysfunction such as Parkinson's disease that can be interfering with outcome assessment based on qualified investigator's judgment.
2. Patients taking tricyclic antidepressant (TCAs)
3. Patients in whom the acute stroke is primarily hemorrhagic
4. Patients with both TIA and atrial fibrillation
5. Patients with both TIA and large vessel disease
6. Patients with inflammatory diseases
```

## Arms

- **AFDAS** — patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring
- **KAF** — atrial fibrillation known before the stroke or transient ischemic attack
- **NSR** — patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring

## Primary Outcomes

- **Changes and Differences in Autonomic Function** _(time frame: Within 48 hours of stroke onset and at 12, 30 and 90 days.)_ — Differences in Composite Autonomic Severity Score (CASS) on an 11-point scale between patients with (a) AFDAS, (b) KAF , and (c) NSR
- **Changes and Differences in Inflammatory Responses** _(time frame: Within 48 hours of stroke onset and at 12, 30 and 90 days.)_ — Differences in levels of plasma markers or temporal responses (CRP,TNFα, IL-6, IL-1β, etc) between patients with (a) AFDAS, (b)KAF and (c) NSR.
- **Changes and Differences in Heart Rate Variability (HRV)** _(time frame: At 14 days.)_ — Differences in HRV parameters between patients with (a) AFDAS, and (b) NSR

## Secondary Outcomes

- **Biomarkers** _(time frame: Within 48 hours of stroke onset, at 12, 30 and 90 days and at 6 months.)_
- **Atrial Fibrillation Burden** _(time frame: At 14 days)_
- **Gait Impairments** _(time frame: At 6 months)_
- **Frailty** _(time frame: At 6 months)_
- **Cognitive Impairment** _(time frame: At 6 months)_

## Locations (1)

- University Hospital, London Helath Sciences Center, London, Ontario, Canada

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university hospital, london helath sciences center|london|ontario|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03275155.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03275155*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*